New drug cocktail aims to shrink tough lung cancers
NCT ID NCT07501169
First seen Apr 01, 2026 · Last updated May 12, 2026 · Updated 7 times
Summary
This study tests a combination of two drugs, sacituzumab tirumotecan and anlotinib, in people with extensive-stage small cell lung cancer whose cancer has come back after prior treatment. The goal is to see if the combo can shrink tumors and delay cancer growth. About 33 adults aged 18 to 75 with good performance status will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
West China Hospital of Sichuan University
Sichuan, Chengdu, 610041, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.